Table 1 Characteristics of included studies
Variables n % unless stated | REVEL | LUME-LUNG 1 | CHECKMATE 017 | CHECKMATE 057 | Hanna | KEYNOTE-010 | POPLAR | TAILOR | OAK | Lux-Lung 8 | HORG | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RAM + DOC n = 628 | PBO + DOC n = 625 | NIN + DOC n = 655 | PBO + DOC n = 659 | NIVO n = 135 | DOC n = 137 | NIVO n = 292 | DOC n = 290 | PEME n = 283 | DOC n = 288 | PEMB n = 344 | DOC n = 343 | ATEZ n = 144 | DOC n = 143 | ERLO n = 109 | DOC n = 110 | ATEZ n = 425 | DOC n = 425 | AFA n = 398 | ERL n = 397 | PEME n = 166 | ERL n = 166 | |
Age, years median, range | 62 21–85 | 61 25–86 | 60 53–67 | 60 54–66 | 62 39–85 | 64 42–84 | 61 37–84 | 64 21–85 | 59 22–81 | 57 28–87 | 63 56–69 | 62 56–69 | 62 42–82 | 62 36–84 | 66 40–81 | 67 35–83 | 63 33–82 | 64 34–85 | 65 36–84 | 64 35–88 | 66 42 86 | 65 37–83 |
Male sex | 419 67 | 415 66 | 476 73 | 479 73 | 111 82 | 97 71 | 151 52 | 168 58 | 194 68.6 | 217 75.3 | 212 62 | 209 61 | 93 65 | 76 53 | 77 71 | 73 66 | 261 61 | 259 61 | 335 84 | 331 83 | 138 83.1 | 135 81.3 |
White | 526 84 | 503 81 | 533 81 | 530 80 | 122 90 | 130 95 | 267 91 | 266 92 | NA | NA | 246 72 | 251 73 | NR | NR | 108 99 | 109 99 | 302 71 | 296 70 | 312 78 | 311 78 | NR | NR |
Asian | 74 12 | 86 14 | 116 18 | 123 19 | 4 3 | 2 1 | 9 3 | 8 3 | 73 21 | 72 21 | NR | NR | 1 1 | 1 1 | 85 20 | 95 22 | 86 22 | 86 22 | NR | NR | ||
Black | 17 3 | 16 3 | 4 < 1 | 5 < 1 | 6 4 | 2 1 | 7 2 | 9 3 | 13 4 | 7 2 | NR | NR | 0 | 0 | 5 1 | 11 3 | NR | NR | NR | NR | ||
PS 0 | 207 33 | 199 32 | 187 29 | 189 29 | 27 20 | 37 27 | 84 29 | 95 33 | 251 88.6 | 252 87.6 | 112 33 | 116 34 | 46 32 | 45 32 | 52 48 | 53 48 | 155 36 | 160 38 | 126 32 | 134 34 | 37 22.3 | 44 26.5 |
PS 1 | 420 67 | 425 68 | 467 71 | 470 71 | 106 79 | 100 73 | 208 71 | 194 67 | 229 67 | 224 65 | 96 68 | 97 68 | 48 44 | 50 45 | 270 64 | 265 62 | 269 68 | 262 66 | 98 59 | 104 62.7 | ||
Current & former smoker | 518 82 | 483 77 | 490 75 | 498 76 | 121 90 | 129 94 | 231 79 | 227 78 | NA | NA | 279 81 | 269 78 | 117 81 | 114 80 | 90 83 | 80 73 | 341 80 | 353 83 | 361 91 | 367 92 | 128 77.1 | 124 74.7 |
Never smoker | 109 17 | 141 23 | 165 25 | 161 24 | 10 7 | 7 5 | 58 20 | 60 21 | 63 18 | 67 20 | 27 19 | 29 20 | 19 17 | 30 27 | 84 20 | 72 17 | 26 7 | 18 5 | 24 14.5 | 29 17.5 | ||
Stage IIIB at inclusion | 0 | 0 | 148 23 | 146 22 | 29 21 | 24 18 | 20 7 | 24 8 | 71 25.1 | 73 25.3 | na | na | NR | NR | NR | NR | NR | NR | 48 12 | 48 12 | 19 11.4 | 12 7.2 |
Stage IV at inclusion | 628,100 | 625,100 | 399 61 | 408 62 | 105 78 | 112 82 | 272 93 | 266 92 | 212 74.9 | 215 74.7 | na | na | NR | NR | NR | NR | NR | NR | 349 88 | 345 87 | 147 88.6 | 154 92.8 |
Non-squamous | 465 74 | 447 72 | 347 53 | 352 53 | 0 | 0 | 292,100 | 290,100 | 154 54.4 | 142 49.3 | 240 70 | 240 70 | 95 66 | 95 66 | 78 71.5 | 87 79 | 313 74 | 315 74 | 17 4 | 15 4 | 130 79.3 | 127 76.5 |
Squamous | 157 25 | 171 27 | 276 42 | 279 42 | 135,100 | 137,100 | 0 | 0 | 78 27.6 | 93 32.3 | 76 22 | 66 19 | 49 34 | 48 34 | 31 28.4 | 23 21 | 112 26 | 110 26 | 381 96 | 382 96 | 36 21.7 | 39 23.5 |
Prior platinum-based therapy | 623 99 | 622 99 | 628 97 | 636 98 | 135,100 | 138,100 | 292,100 | 290,100 | 262 92.6 | 259 89.9 | na | na | NR | NR | 109,100 | 110,100 | 425,100 | 425,100 | 398,100 | 397,100 | 166,100 | 166,100 |
First-line bevacizumab | 88 14 | 92 15 | 27 4 | 23 4 | 1 1 | 2 1 | na | na | 0 | 0 | na | na | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Prior maintenance treatment | 135 21 | 143 23 | NA | NA | NA | NA | 122 42 | 111 38 | NA | NA | na | na | 144,100 | 143,100 | 109,100 | 109 99 | NR | NR | NR | NR | NR | |
Previous taxane | 153 24 | 152 24 | NA | NA | 46 34 | 46 34 | na | na | 73 25.8 | 80 27.8 | na | na | NR | NR | 0 | 0 | NR | NR | NR | NR | NR | NR |
EGFR Wild type | 207 33 | 197 32 | NA | NA | NA | NA | na | na | NA | NA | 293 85 | 294 86 | NR | NR | 109,100 | 110,100 | 318 75 | 310 73 | NR | NR | 57 / 62 | 55 / 61 |
EGFR Mutant | 15 2 | 18 3 | NA | NA | NA | NA | 44 15 | 38 13 | 28 8 | 26 8 | 10 12 | 8 10 | 0 | 0 | 42 10 | 43 10 | NR | NR | 5 / 62 | 6 / 61 | ||
Unknown or missing | 406 65 | 410 66 | NA | NA | NA | NA | na | na | 23 7 | 23 7 | NR | NR | 0 | 0 | 65 15 | 72 17 | NR | NR | NR | NR | ||
1 prior therapy | 628,100 | 625,100 | 655,100 | 659,100 | 135,100 | 137,100 | 292,100 | 290,100 | 283,100 | 288,100 | 243 71 | 235 69 | 93 65 | 96 67 | unclear | unclear | 320 75 | 320 75 | 398,100 | 397,100 | 101 60.8 | 89 53.6 |
2 prior therapies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 66 19 | 75 22 | 51 35 | 47 33 | Â | Â | 105 25 | 105 25 | 0 | 0 | 65 39.2 | 77 46.4 |